GlassScriptPhysician profile
James W Fetchero
NPI 1750301586
$2,593.22
in general payments reported to CMS, 2019-2025
31 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $214 · 2021: $487 · 2022: $431 · 2023: $506 · 2024: $561 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.04 | 2021-2024 | |
| Novo Nordisk INC | $312.85 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $164.62 | 2023-2024 | Korlym |
| Lilly USA, LLC | $154.10 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $117.67 | 2021-2024 | |
| Abbott Laboratories | $108.78 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $103.65 | 2023-2024 | Quviviq |
| Edwards Lifesciences Corporation | $99.80 | 2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $99.06 | 2023-2024 | |
| Astellas Pharma US INC | $91.38 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $81.48 | 2021-2022 | |
| Abiomed | $78.86 | 2025 | |
| Amgen INC. | $78.01 | 2019-2024 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.10 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.46 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $38.75 | 2019 | |
| Exact Sciences Corporation | $32.85 | 2023-2024 | Cologuard Collection Kit |
| Bridgebio Pharma, INC. | $30.49 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $30.44 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.65 | 2023 | Seglentis, Livalo |
| Boston Scientific Corporation | $28.64 | 2023 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $26.53 | 2024 | Rexulti |
| Allergan, INC. | $25.42 | 2020 | |
| Phathom Pharmaceuticals, INC. | $25.15 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $24.59 | 2023 | Heplisav-B |
| Biogen, INC. | $20.93 | 2020 | |
| Irhythm Technologies, INC. | $17.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.15 | 2021 | |
| Medtronic, INC. | $13.09 | 2022 | |
| Glaxosmithkline, LLC. | $12.35 | 2020 | |
| Amarin Pharma, INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fetchero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.